SEC Form 4 · accession 0001764013-26-000075
Immunovant, Inc. · IMVT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Melanie Gloria
Officer — Chief Operating Officer
Period of report
Jun 26, 2026
Accepted (ET)
Jun 26, 2026 · 7:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001764013
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 26, 2026 | S | 14,748 | $38.18 | D | 227,359 | D | |
| Common StockF2 | Jun 26, 2026 | S | 2,966 | $38.95 | D | 224,393 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.78 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.